Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: the value and limitations of clinical factors

177 Lu-Dota-octreotate radionuclide therapy of advanced gastrointestinal neuroendocrine tumors: results from a phase II study

(2014) Giovanni Paganelli et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Peptide receptor therapies in neuroendocrine tumors

(2014) L. Bodei et al.   JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION

Recommendations for management of patients with neuroendocrine liver metastases

(2014) Andrea Frilling et al.   LANCET ONCOLOGY

The evolving challenge of therapy-related myeloid neoplasms

(2013) Jane E. Churpek et al.   BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY

Accurate assessment of long-term nephrotoxicity after peptide receptor radionuclide therapy with 177Lu-octreotate

(2013) Amir Sabet et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Experimental facts supporting a red marrow uptake due to radiometal transchelation in 90Y-DOTATOC therapy and relationship to the decrease of platelet counts

(2011) Stephan Walrand et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Peptide receptor radionuclide therapy with 177Lu-DOTATATE: the IEO phase I-II study

(2011) Lisa Bodei et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Therapy-related myeloid neoplasms following treatment with radioiodine

(2011) T. Schroeder et al.   HAEMATOLOGICA

Response, Survival, and Long-Term Toxicity After Therapy With the Radiolabeled Somatostatin Analogue [90Y-DOTA]-TOC in Metastasized Neuroendocrine Cancers

(2011) Anna Imhof et al.   JOURNAL OF CLINICAL ONCOLOGY

Quality of Life in 265 Patients with Gastroenteropancreatic or Bronchial Neuroendocrine Tumors Treated with [177Lu-DOTA0,Tyr3]Octreotate

(2011) S. Khan et al.   JOURNAL OF NUCLEAR MEDICINE

The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML

(2010) S. Kayser et al.   BLOOD

90Y-Edotreotide for Metastatic Carcinoid Refractory to Octreotide

(2010) David L. Bushnell et al.   JOURNAL OF CLINICAL ONCOLOGY

Renal Toxicity of Radiolabeled Peptides and Antibody Fragments: Mechanisms, Impact on Radionuclide Therapy, and Strategies for Prevention

(2010) E. Vegt et al.   JOURNAL OF NUCLEAR MEDICINE

Somatostatin receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors

(2009) Dik J Kwekkeboom et al.   ENDOCRINE-RELATED CANCER

Renal Function Assessment in the Era of Chronic Kidney Disease: Renewed Emphasis on Renal Function Centered Patient Care

(2009) Brian R. Lane et al.   JOURNAL OF UROLOGY

Suppression of the DNA damage response in acute myeloid leukemia versus myelodysplastic syndrome

(2009) S Boehrer et al.   ONCOGENE

Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: the role of associated risk factors

(2008) Lisa Bodei et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Treatment With the Radiolabeled Somatostatin Analog [177Lu-DOTA0,Tyr3]Octreotate: Toxicity, Efficacy, and Survival

(2008) Dik J. Kwekkeboom et al.   JOURNAL OF CLINICAL ONCOLOGY

Therapy-Related Myeloid Leukemia

(2008) Lucy A. Godley et al.   SEMINARS IN ONCOLOGY